Posts by: Joana Carvalho, PhD

Joana Carvalho, PhD

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

March 25, 2020March 25, 2020

Tekturna Seen to Treat High Blood Pressure Associated with aHUS

News

A medication for high blood pressure, Tekturna (aliskiren) may be used as an add-on therapy to manage hypertension associated with atypical hemolytic uremic syndrome (aHUS) until more adequate treatments become available, ... Read more

February 10, 2020February 10, 2020

Understanding aHUS-linked Changes in Large Gene Cluster May Help in Diagnosis and Treatment, Review Says

News

Understanding the disease-related alterations in a large gene cluster that lead to atypical hemolytic uremic syndrome (aHUS) may help in diagnosing and treating the illness, a recent review suggests. ... Read more

January 27, 2020January 27, 2020

Experts Propose New Diagnostic Criteria to Distinguish TMA Associated With aHUS

News

Experts in South Korea have proposed a set of new diagnostic criteria to distinguish thrombotic microangiopathy associated with atypical hemolytic uremic syndrome (aHUS). Their study, “Consensus regarding diagnosis and ... Read more

October 23, 2019October 23, 2019

FDA Approves Alexion’s Ultomiris for Treating aHUS in Children and Adults

News

The U.S. Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvz) for the treatment of adults and children ages one month and older with atypical hemolytic uremic syndrome (aHUS), ... Read more

August 7, 2019August 7, 2019

Multidisciplinary Approach Needed to Evaluate Patients Suspected of Having aHUS, Case Report Says

News

A multidisciplinary approach is needed to evaluate patients suspected of having atypical hemolytic uremic syndrome (aHUS) and to select the best course of treatment in each instance, a case ... Read more

June 26, 2019June 26, 2019

FDA Grants Priority Review to sBLA of Ultomiris for Treatment of aHUS

News

The U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for Alexion‘s Ultomiris (ravulizumab-cwvz) for the treatment of patients with atypical ... Read more

June 5, 2019June 5, 2019

aHUS May be Associated With Heart Disease, Case Report Shows

News

In some patients, atypical hemolytic uremic syndrome (aHUS) may be associated with heart disease, a case report study highlights. The case report study, “Atypical Hemolytic Uremic Syndrome Presenting as ... Read more

May 23, 2019May 23, 2019

Rapid Drug Desensitization Allowed Child With aHUS to Continue Soliris Treatment, Case Report Says

News

Rapid drug desensitization may allow patients with atypical hemolytic uremic syndrome (aHUS) to continue treatment with Soliris (eculizumab), following a medicine-induced allergic reaction, a case report says. The study, ... Read more

April 3, 2019April 3, 2019

Hypertensive Emergency, Complement Mutations Key to aHUS Prognosis, Study Says

News

Hypertensive emergency and the presence of rare complement mutations are essential to estimate the prognosis of kidney disease in patients with atypical hemolytic uremic syndrome (aHUS). The study, “Impact Of ... Read more

February 15, 2019February 15, 2019

Scientists Create New Mouse Model for Atypical Hemolytic Uremic Syndrome

News

Scientists have created a new mouse model for atypical hemolytic uremic syndrome (aHUS) that fully mirrors the clinical symptoms of the disease seen in human patients. The animals, which ... Read more

Pin It on Pinterest